{"id":3601,"date":"2025-03-07T10:27:09","date_gmt":"2025-03-07T10:27:09","guid":{"rendered":"https:\/\/smartdelta.in\/blogs\/?p=3601"},"modified":"2025-03-07T10:27:10","modified_gmt":"2025-03-07T10:27:10","slug":"rubicon-research-ltd-ipo","status":"publish","type":"post","link":"https:\/\/smartdelta.in\/blogs\/ipo\/rubicon-research-ltd-ipo\/","title":{"rendered":"Rubicon Research Ltd IPO: Financial Highlights and Growth Prospects"},"content":{"rendered":"\n<p><strong>Rubicon Research Limited<\/strong>, a leading Indian pharmaceutical company, is set to launch its <strong>Initial Public Offering (IPO)<\/strong>, providing an opportunity for investors to participate in the growth of a company focused on innovation and research in the highly regulated pharmaceutical industry. With a strong presence in the <strong>U.S. market<\/strong>, Rubicon Research is poised for expansion and continued success.<\/p>\n\n\n<ul><li><a class=\"aioseo-toc-item\" href=\"#aioseo-company-overview-rubicon-research-limited\">Company Overview: Rubicon Research Limited<\/a><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-rubicon-research-ipo-details\">Rubicon Research IPO Details<\/a><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-financial-overview\">Financial Overview<\/a><ul><li><a class=\"aioseo-toc-item\" href=\"#aioseo-profit-loss-in-crores\">Profit &amp; Loss (\u20b9 in Crores)<\/a><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-balance-sheet-in-crores\">Balance Sheet (\u20b9 in Crores)<\/a><\/li><\/ul><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-strengths-of-rubicon-research\">Strengths of Rubicon Research<\/a><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-risks-and-challenges\">Risks and Challenges<\/a><\/li><li><a class=\"aioseo-toc-item\" href=\"#aioseo-conclusion-why-invest-in-rubicon-research-ipo\">Conclusion: Why Invest in Rubicon Research IPO?<\/a><\/li><\/ul>\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-company-overview-rubicon-research-limited\"><strong>Company Overview: Rubicon Research Limited<\/strong><\/h3>\n\n\n\n<p>Founded in <strong>1999<\/strong>, <strong>Rubicon Research Ltd<\/strong> is a pharmaceutical company headquartered in <strong>Thane<\/strong>, India. The company specializes in the development, manufacturing, and marketing of a diverse range of <strong>pharmaceutical formulations<\/strong>. Rubicon has made its mark by focusing on <strong>research and development (R&amp;D)<\/strong>, with a portfolio of products that are primarily aimed at <strong>regulated markets<\/strong>, particularly the <strong>United States<\/strong>.<\/p>\n\n\n\n<p>Rubicon operates <strong>two R&amp;D facilities<\/strong>, one in <strong>India<\/strong> and one in <strong>Canada<\/strong>, both of which are inspected by the <strong>US FDA<\/strong>. Additionally, the company has <strong>two manufacturing plants<\/strong> in Maharashtra, India, accredited by global regulatory bodies like <strong>US FDA<\/strong>, <strong>WHO-GMP<\/strong>, and <strong>Health Canada<\/strong>. As of <strong>March 31, 2024<\/strong>, Rubicon has <strong>69 FDA-approved products<\/strong>, with <strong>19 applications under review<\/strong> and <strong>46 products in development<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-rubicon-research-ipo-details\"><strong>Rubicon Research IPO Details<\/strong><\/h3>\n\n\n\n<p>The upcoming <strong>Rubicon Research IPO<\/strong> is structured as a <strong>book-built issue<\/strong> with a total issue size of <strong>\u20b91,085 crores<\/strong>. The funds raised from the IPO will be used to <strong>repay borrowings<\/strong>, <strong>finance acquisitions<\/strong>, and meet <strong>general corporate purposes<\/strong>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fresh Issue<\/strong>: \u20b9500 crores<\/li>\n\n\n\n<li><strong>Offer for Sale (OFS)<\/strong>: \u20b9585 crores<\/li>\n<\/ul>\n\n\n\n<p><strong>IPO Price Band<\/strong>: \u20b9805 per share (tentative)<br><strong>IPO Open Date<\/strong>: 21 April 2025 (expected)<br><strong>IPO Close Date<\/strong>: 23 April 2025 (expected)<br><strong>Listing Date<\/strong>: 28 April 2025 (expected)<br><strong>Listing at<\/strong>: BSE, NSE<\/p>\n\n\n\n<p><strong>Shares Allocation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>75% for Qualified Institutional Buyers (QIBs)<\/strong><\/li>\n\n\n\n<li><strong>15% for Non-Institutional Investors (NIIs)<\/strong><\/li>\n\n\n\n<li><strong>10% for Retail Individual Investors (RIIs)<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-financial-overview\"><strong>Financial Overview<\/strong><\/h3>\n\n\n\n<p>Rubicon Research has demonstrated strong growth in revenue, although it has faced challenges in profitability. Below is a summary of Rubicon\u2019s key financial metrics over the past few years:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"aioseo-profit-loss-in-crores\"><strong>Profit &amp; Loss (\u20b9 in Crores)<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Particulars<\/strong><\/td><td><strong>FY 2024<\/strong><\/td><td><strong>FY 2023<\/strong><\/td><td><strong>FY 2022<\/strong><\/td><\/tr><tr><td><strong>Net Revenue<\/strong><\/td><td>\u20b9872.39<\/td><td>\u20b9419<\/td><td>\u20b9330.42<\/td><\/tr><tr><td><strong>Total Expenses<\/strong><\/td><td>\u20b9769.53<\/td><td>\u20b9430.05<\/td><td>\u20b9396.53<\/td><\/tr><tr><td><strong>Profit After Tax<\/strong><\/td><td>\u20b991.01<\/td><td>-\u20b916.89<\/td><td>-\u20b967.12<\/td><\/tr><tr><td><strong>EBITDA<\/strong><\/td><td>\u20b9173.09<\/td><td>\u20b943.97<\/td><td>-\u20b922.38<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"aioseo-balance-sheet-in-crores\"><strong>Balance Sheet (\u20b9 in Crores)<\/strong><\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Particulars<\/strong><\/td><td><strong>FY 2024<\/strong><\/td><td><strong>FY 2023<\/strong><\/td><td><strong>FY 2022<\/strong><\/td><\/tr><tr><td><strong>Net Worth<\/strong><\/td><td>\u20b9385<\/td><td>\u20b9286.38<\/td><td>\u20b9428.61<\/td><\/tr><tr><td><strong>Reserves &amp; Surplus<\/strong><\/td><td>\u20b9369.79<\/td><td>\u20b9281.30<\/td><td>\u20b9423.54<\/td><\/tr><tr><td><strong>Total Borrowings<\/strong><\/td><td>\u20b9396.41<\/td><td>\u20b9317.91<\/td><td>\u20b9169.19<\/td><\/tr><tr><td><strong>Total Assets<\/strong><\/td><td>\u20b91,109.49<\/td><td>\u20b9749.70<\/td><td>\u20b9559.52<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-strengths-of-rubicon-research\"><strong>Strengths of Rubicon Research<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Leading Focus on the U.S. Market<\/strong>: Rubicon is the <strong>fastest growing Indian pharmaceutical company<\/strong> among its peers and is uniquely focused on <strong>U.S. markets<\/strong>, making it well-positioned for growth in the largest pharmaceutical market globally.<\/li>\n\n\n\n<li><strong>Robust Product Portfolio<\/strong>: With <strong>69 FDA-approved products<\/strong>, Rubicon has established a strong portfolio that allows it to maintain competitive pricing, even in challenging market conditions.<\/li>\n\n\n\n<li><strong>R&amp;D Capabilities<\/strong>: The company\u2019s investment in <strong>R&amp;D<\/strong> ensures that it stays at the forefront of pharmaceutical innovation, developing complex products with high revenue potential.<\/li>\n\n\n\n<li><strong>Regulatory Compliance<\/strong>: Rubicon\u2019s plants are <strong>US FDA-approved<\/strong>, showcasing its commitment to maintaining high manufacturing standards that align with global regulatory requirements.<\/li>\n\n\n\n<li><strong>Experienced Management<\/strong>: The company boasts an <strong>entrepreneurial management team<\/strong> and has strong backing from <strong>marquee private equity investors<\/strong>, providing Rubicon with the leadership needed to achieve long-term success.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-risks-and-challenges\"><strong>Risks and Challenges<\/strong><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Heavy Dependence on U.S. Market<\/strong>: <strong>97.4%<\/strong> of Rubicon\u2019s revenue comes from the <strong>U.S. market<\/strong>, making the company highly vulnerable to any adverse developments in this region, such as regulatory changes or market fluctuations.<\/li>\n\n\n\n<li><strong>Regulatory Risks<\/strong>: As a <strong>highly regulated industry<\/strong>, pharmaceutical manufacturing carries significant risks. <strong>Product recalls<\/strong>, <strong>inspection failures<\/strong>, or <strong>facility shutdowns<\/strong> could negatively affect the company\u2019s operations and revenues.<\/li>\n\n\n\n<li><strong>R&amp;D Uncertainty<\/strong>: While Rubicon invests heavily in <strong>R&amp;D<\/strong>, there is no guarantee that these efforts will always lead to marketable products. Failure to successfully develop and market new products could harm the company\u2019s revenue growth.<\/li>\n\n\n\n<li><strong>Customer Concentration<\/strong>: Rubicon derives a significant portion of its revenue from its top <strong>five customers<\/strong>. The <strong>loss of any key customer<\/strong> could severely impact the company\u2019s financial performance.<\/li>\n\n\n\n<li><strong>Competitive Pressures<\/strong>: The pharmaceutical industry is highly competitive, with numerous players vying for market share. Rubicon must continue to innovate and manage costs effectively to maintain its competitive edge.<\/li>\n\n\n\n<li><strong>Disruptions in Operations<\/strong>: Any <strong>disruption, breakdown, or shutdown<\/strong> of the company\u2019s <strong>R&amp;D or manufacturing facilities<\/strong> could have a material adverse effect on its business and financial performance.<\/li>\n<\/ol>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"aioseo-conclusion-why-invest-in-rubicon-research-ipo\"><strong>Conclusion: Why Invest in Rubicon Research IPO?<\/strong><\/h3>\n\n\n\n<p>The <strong>Rubicon Research IPO<\/strong> offers investors the opportunity to participate in a rapidly growing pharmaceutical company with a strong focus on <strong>regulated markets<\/strong>, particularly the <strong>U.S.<\/strong> With its innovative product portfolio, solid R&amp;D capabilities, and established market presence, Rubicon is poised for long-term growth.<\/p>\n\n\n\n<p>However, the company\u2019s heavy dependence on the U.S. market, regulatory risks, and customer concentration should be carefully considered. Investors should conduct thorough due diligence to understand the company\u2019s risks and growth potential before making an investment decision.<\/p>\n\n\n\n<p><strong>Source:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/zerodha.com\/ipo\/391199\/rubicon-research\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/bigul.co\/blog\/ipo\/rubicon-research-ipo-open-date-ipo-gmp-priceband-allotment-drhp\n<\/div><\/figure>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/www.bajajbroking.in\/ipo\/rubicon-research-limited-ipo\n<\/div><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rubicon Research Limited, a leading Indian pharmaceutical company, is set to launch its Initial Public Offering (IPO), providing an opportunity for investors to participate in the growth of a company focused on innovation and research in the highly regulated pharmaceutical industry. With a strong presence in the U.S. market, Rubicon Research is poised for expansion [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3603,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo"],"blocksy_meta":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/posts\/3601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/comments?post=3601"}],"version-history":[{"count":1,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/posts\/3601\/revisions"}],"predecessor-version":[{"id":3602,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/posts\/3601\/revisions\/3602"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/media\/3603"}],"wp:attachment":[{"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/media?parent=3601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/categories?post=3601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartdelta.in\/blogs\/wp-json\/wp\/v2\/tags?post=3601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}